clofibric acid has been researched along with Chronic Kidney Failure in 11 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bezafibrate treatment resulted in significant decrease in the serum concentrations of triglycerides, total cholesterol and LDL-cholesterol, whereas HDL-cholesterol serum levels increased." | 2.65 | Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients. ( Grützmacher, P; Lang, W; Scheuermann, E, 1981) |
| "The evidence to support treating dyslipidemia in hemodialysis patients, however, has been mixed, with several outcome trials pending." | 2.44 | Managing dyslipidemia in chronic kidney disease. ( Harper, CR; Jacobson, TA, 2008) |
| "As a basis for establishing dosing guidelines in order to avoid side effects due to overdosage, the concentrations of total and free non-protein bound clofibrinic acid (CA) were determined before and after the administration of a single clofibrate dose (0, 2, 6, 12, 24, 48, 72, 96h) in patients with various degrees of impaired renal function and in a control group (n = 56)." | 1.27 | Serum levels of free non-protein bound clofibrinic acid after single dosing to patients with impaired renal function of various degrees--a multicenter study. ( Graben, N; Hartmann, H; Merk, W; Nikolaus, C; Schlierf, G; Schwandt, P, 1987) |
| " The recommended dosage of clofibrate is 1." | 1.26 | [Fat and renal failure--therapeutic aspects]. ( Heidland, A; Hörl, M; Hörl, WH, 1982) |
| " An individualized dosage of bezafibrate and repeated checks of the serum concentrations of the drug are recommended during long-term treatment of uremic patients." | 1.26 | Treatment of uremic hypertriglyceridaemia with bezafibrate. ( Anderson, P; Norbeck, HE, 1982) |
| " Eight of the patients had moderately impaired renal function, with a creatinine clearance between 20 and 40 ml/min; the mean plasma half-life of bezafibrate in them was 7." | 1.26 | Clinical pharmacokinetics of bezafibrate in patients with impaired renal function. ( Anderson, P; Norbeck, HE, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (81.82) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harper, CR | 1 |
| Jacobson, TA | 1 |
| Huang, JW | 1 |
| Yen, CJ | 1 |
| Chiang, HW | 1 |
| Hung, KY | 1 |
| Tsai, TJ | 1 |
| Wu, KD | 1 |
| Robertz, GM | 1 |
| Dengler, HJ | 1 |
| Grützmacher, P | 1 |
| Scheuermann, E | 1 |
| Lang, W | 1 |
| Lacour, B | 1 |
| Di Giulio, S | 1 |
| Nicolaï, A | 1 |
| Drüeke, T | 1 |
| Debray, M | 1 |
| Boulu, RG | 1 |
| Hörl, WH | 1 |
| Hörl, M | 1 |
| Heidland, A | 1 |
| Norbeck, HE | 2 |
| Anderson, P | 2 |
| Bjornsson, TD | 1 |
| Meffin, PJ | 1 |
| Peters, FA | 1 |
| Blaschke, TF | 1 |
| Kasiske, BL | 1 |
| O'Donnell, MP | 1 |
| Garvis, WJ | 1 |
| Keane, WF | 1 |
| Merk, W | 1 |
| Graben, N | 1 |
| Hartmann, H | 1 |
| Nikolaus, C | 1 |
| Schlierf, G | 1 |
| Schwandt, P | 1 |
1 review available for clofibric acid and Chronic Kidney Failure
| Article | Year |
|---|---|
Managing dyslipidemia in chronic kidney disease.
Topics: Algorithms; Anticholesteremic Agents; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Fatty | 2008 |
1 trial available for clofibric acid and Chronic Kidney Failure
| Article | Year |
|---|---|
Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
Topics: Adult; Bezafibrate; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Humans; Hyper | 1981 |
9 other studies available for clofibric acid and Chronic Kidney Failure
| Article | Year |
|---|---|
Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function.
Topics: Adiponectin; Aged; Body Mass Index; Clofibric Acid; Coronary Vessels; Diabetes Mellitus; Echocardiog | 2004 |
Endogenous ligand(s) decrease drug--protein binding in uremic sera: a fluorescence probe study.
Topics: Adult; Clofibrate; Clofibric Acid; Dansyl Compounds; Female; Fluorescent Dyes; Glycine; Humans; Kidn | 1983 |
[Study of the binding characteristics of chlorophenoxyisobutyric acid to serum proteins in chronically uremic patients : influence of dialysis and heparine (author's transl)].
Topics: Binding, Competitive; Blood Proteins; Clofibrate; Clofibric Acid; Dialysis; Heparin; Humans; In Vitr | 1982 |
[Fat and renal failure--therapeutic aspects].
Topics: Acute Kidney Injury; Animals; Bezafibrate; Carnitine; Charcoal; Clofibrate; Clofibric Acid; Humans; | 1982 |
Treatment of uremic hypertriglyceridaemia with bezafibrate.
Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipidemias; Kidney Failur | 1982 |
Clinical pharmacokinetics of bezafibrate in patients with impaired renal function.
Topics: Adult; Aged; Bezafibrate; Clofibrate; Clofibric Acid; Creatinine; Female; Humans; Hyperlipidemias; H | 1981 |
Saliva and plasma levels and plasma protein binding of clofibrinic acid in uremic patients.
Topics: Adult; Aged; Blood Proteins; Clofibrate; Clofibric Acid; Humans; Kidney Failure, Chronic; Middle Age | 1980 |
Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure.
Topics: Animals; Cholesterol; Clofibrate; Clofibric Acid; Disease Models, Animal; Glomerulonephritis; Glomer | 1988 |
Serum levels of free non-protein bound clofibrinic acid after single dosing to patients with impaired renal function of various degrees--a multicenter study.
Topics: Adult; Clofibrate; Clofibric Acid; Creatinine; Female; Humans; Kidney Failure, Chronic; Kinetics; Ma | 1987 |